SAHA treatment upregulates Abcd2 and Abcd3 levels in Abcd1-deficient U87 astrocytes and B12 oligodendrocytes.

<p>There was no change in Abcd1 protein levels (<b>A-i and E-i</b>) and mRNA expression (<b>A-ii and E-ii</b>) in Abcd1-deficient U87 astrocytes and B12 oligodendrocytes treated with SAHA. Abcd2 (<b>B and F</b>) and Abcd3 (<b>C and G</b>) protein levels (<b>i</b>) and mRNA expression (<b>ii</b>) in control, NT and Abcd1-deficient U87 astrocytes and B12 oligodendrocytes respectively (n = 3) treated with SAHA dose-dependently. Protein levels of the peroxisomal transporters Abcd1 (<b>A-i and E-i</b>), Abcd2 (<b>B-i and F-i</b>) and Abcd3 (<b>C-i and G-i</b>) were analyzed by Western analysis of peroxisomal membrane fractions obtained by carbonate treatment (membrane preparation containing integral membrane proteins), as indicated in Methods section. Na<sup>+</sup>/K<sup>+</sup>-ATPase (plasma membrane protein) was used as indicator of protein loading for plasma membrane fractions. Abcd1 (<b>A-ii and E-ii</b>), Abcd2 (<b>B-ii and F-ii</b>) and Abcd3 (<b>C-ii and G-ii</b>) mRNA levels were determined by qRT–PCR and normalized to GAPDH. Data are represented as mean±SD. <sup>@</sup>P<0.001 Abcd1-Lenti compared to control or NT cells; **P<0.001 SAHA (5.0 µM) treatment compared to Abcd1-Lenti; *P<0.005 SAHA treatment compared to Abcd1-Lenti; <sup>@@</sup>P<0.001 SAHA treatment compared to Abcd1-Lenti; NS, non-significant; SA, SAHA.</p>